ExtraCellular Matrix Hydrogel (ECMH)

The first non-surgical treatment option for Ulcerative Colitis

REGENTYS™ is a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders.

Our first product, ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis

Regentys Named Finalist!

June 28, 2018 — Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected 11 Patient Entrepreneur finalists who will compete in the “Empowering Patients: An Innovation Challenge” to earn the Lyfebulb and UnitedHealth Group Innovation Award.

Read More

Vision Statement

To provide patients suffering with IBD, and other diseases of the lower GI and urogenital tract, regenerative medicine treatments for their disease, to improve their quality of life.

Mission Statement

We are a development stage regenerative medicine company whose mission is to develop novel applications of extracellular matrix to treat IBD and put patients suffering with the disease into deep remission.